{
    "info": {
        "nct_id": "NCT04101331",
        "official_title": "A Phase II Open-label Multicenter Study to Assess the Efficacy and Safety of AFM13 in Patients With Relapsed or Refractory CD30-positive Peripheral T-cell Lymphoma or Transformed Mycosis Fungoides (REDIRECT)",
        "inclusion_criteria": "* Histologically confirmed CD30-positive PTCL (most subtypes allowed) or TMF per the revised World Health Organization 2016 classification (Swerdlow, 2016) by central assessment.\n* Cohorts A and B (PTCL cohorts): measurable by the modified Lugano Classification (Cheson, 2014); measurable disease of ≥1.5 cm diameter by computed tomography (CT), assessed locally for eligibility. Note: fluorodeoxyglucose (FDG) avid disease by positron emission tomography (PET) recommended, if possible.\n* Cohort C (TMF cohort): measurable by the Olsen Criteria (Olsen, 2011) including at least 1 cutaneous lymphoma lesion ≥2 cm in diameter, assessed locally for eligibility.\n* Patients must have relapsed or refractory disease AND the following:\n* Cohorts A and B (PTCL): patients must have received at least 1 prior line of systemic therapy. For patients with systemic ALCL, patients must have failed or be intolerant to brentuximab vedotin [BV]; Adcetris®\n* Cohort C (TMF): patients must have received at least 1 prior line of systemic therapy; and have exhausted systemic therapies with regular approval for their disease\n\nMain\nHealthy volunteers allowed\nMust have minimum age of 18 Years",
        "exclusion_criteria": "* Patients with the following subtypes of lymphoma: T-cell prolymphocytic leukemia; T-cell large granular lymphocytic leukemia; Chronic lymphoproliferative disorder of NK cells; Aggressive NK-cell leukemia; Extranodal NK-/T-cell lymphoma; Indolent T-cell lymphoproliferative disorder of the GI tract:\n* Has had an allogenic tissue hematopoietic cell/solid organ transplant within the last 3 years. Note: Patients who have had a transplant >3 years ago are eligible as long as there are no signs/symptoms of graft versus host disease (GvHD).\n* Requirement for systemic immunosuppressive therapy, e.g. GvHD therapy, <12 weeks prior to the first dose of study drug.\n* Prior treatment with AFM13",
        "miscellaneous_criteria": "Main"
    },
    "inclusion_lines": [
        {
            "line": "Must have minimum age of 18 Years",
            "criterions": [
                {
                    "exact_snippets": "minimum age of 18 Years",
                    "criterion": "age",
                    "requirements": [
                        {
                            "requirement_type": "minimum",
                            "expected_value": {
                                "operator": ">=",
                                "value": 18,
                                "unit": "years"
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Patients must have relapsed or refractory disease AND the following:",
            "criterions": [
                {
                    "exact_snippets": "Patients must have relapsed or refractory disease",
                    "criterion": "disease status",
                    "requirements": [
                        {
                            "requirement_type": "status",
                            "expected_value": [
                                "relapsed",
                                "refractory"
                            ]
                        }
                    ]
                }
            ]
        },
        {
            "line": "Healthy volunteers allowed",
            "criterions": [
                {
                    "exact_snippets": "Healthy volunteers allowed",
                    "criterion": "healthy volunteer status",
                    "requirements": [
                        {
                            "requirement_type": "eligibility",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Cohorts A and B (PTCL): patients must have received at least 1 prior line of systemic therapy. For patients with systemic ALCL, patients must have failed or be intolerant to brentuximab vedotin [BV]; Adcetris®",
            "criterions": [
                {
                    "exact_snippets": "patients must have received at least 1 prior line of systemic therapy",
                    "criterion": "prior lines of systemic therapy",
                    "requirements": [
                        {
                            "requirement_type": "quantity",
                            "expected_value": {
                                "operator": ">=",
                                "value": 1,
                                "unit": "lines"
                            }
                        }
                    ]
                },
                {
                    "exact_snippets": "For patients with systemic ALCL, patients must have failed or be intolerant to brentuximab vedotin [BV]; Adcetris®",
                    "criterion": "response to brentuximab vedotin (Adcetris)",
                    "requirements": [
                        {
                            "requirement_type": "tolerance or response",
                            "expected_value": [
                                "failed",
                                "intolerant"
                            ]
                        }
                    ]
                }
            ]
        },
        {
            "line": "Main",
            "criterions": [
                {
                    "exact_snippets": "Main",
                    "criterion": "main inclusion criteria",
                    "requirements": [
                        {
                            "requirement_type": "N/A",
                            "expected_value": "main inclusion criteria"
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Cohort C (TMF cohort): measurable by the Olsen Criteria (Olsen, 2011) including at least 1 cutaneous lymphoma lesion ≥2 cm in diameter, assessed locally for eligibility.",
            "criterions": [
                {
                    "exact_snippets": "measurable by the Olsen Criteria (Olsen, 2011)",
                    "criterion": "disease measurability by Olsen Criteria",
                    "requirements": [
                        {
                            "requirement_type": "measurability",
                            "expected_value": "Olsen Criteria (Olsen, 2011)"
                        }
                    ]
                },
                {
                    "exact_snippets": "including at least 1 cutaneous lymphoma lesion ≥2 cm in diameter",
                    "criterion": "cutaneous lymphoma lesion",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": true
                        },
                        {
                            "requirement_type": "quantity",
                            "expected_value": {
                                "operator": ">=",
                                "value": 1,
                                "unit": "lesion"
                            }
                        },
                        {
                            "requirement_type": "size",
                            "expected_value": {
                                "operator": ">=",
                                "value": 2,
                                "unit": "cm"
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Histologically confirmed CD30-positive PTCL (most subtypes allowed) or TMF per the revised World Health Organization 2016 classification (Swerdlow, 2016) by central assessment.",
            "criterions": [
                {
                    "exact_snippets": "Histologically confirmed CD30-positive PTCL (most subtypes allowed)",
                    "criterion": "PTCL (Peripheral T-cell lymphoma)",
                    "requirements": [
                        {
                            "requirement_type": "histological confirmation",
                            "expected_value": true
                        },
                        {
                            "requirement_type": "CD30 expression",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "TMF per the revised World Health Organization 2016 classification (Swerdlow, 2016) by central assessment",
                    "criterion": "TMF (transformed mycosis fungoides)",
                    "requirements": [
                        {
                            "requirement_type": "diagnosis per WHO 2016 classification",
                            "expected_value": true
                        },
                        {
                            "requirement_type": "central assessment",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Cohorts A and B (PTCL cohorts): measurable by the modified Lugano Classification (Cheson, 2014); measurable disease of ≥1.5 cm diameter by computed tomography (CT), assessed locally for eligibility. Note: fluorodeoxyglucose (FDG) avid disease by positron emission tomography (PET) recommended, if possible.",
            "criterions": [
                {
                    "exact_snippets": "measurable by the modified Lugano Classification (Cheson, 2014)",
                    "criterion": "disease measurability (Lugano Classification)",
                    "requirements": [
                        {
                            "requirement_type": "measurability",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "measurable disease of ≥1.5 cm diameter by computed tomography (CT), assessed locally for eligibility",
                    "criterion": "disease size by CT",
                    "requirements": [
                        {
                            "requirement_type": "size",
                            "expected_value": {
                                "operator": ">=",
                                "value": 1.5,
                                "unit": "cm"
                            }
                        },
                        {
                            "requirement_type": "measurability by CT",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "fluorodeoxyglucose (FDG) avid disease by positron emission tomography (PET) recommended, if possible",
                    "criterion": "FDG avid disease by PET",
                    "requirements": [
                        {
                            "requirement_type": "FDG avidity by PET",
                            "expected_value": "recommended"
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Cohort C (TMF): patients must have received at least 1 prior line of systemic therapy; and have exhausted systemic therapies with regular approval for their disease",
            "criterions": [
                {
                    "exact_snippets": "patients must have received at least 1 prior line of systemic therapy",
                    "criterion": "prior lines of systemic therapy",
                    "requirements": [
                        {
                            "requirement_type": "quantity",
                            "expected_value": {
                                "operator": ">=",
                                "value": 1,
                                "unit": "line"
                            }
                        }
                    ]
                },
                {
                    "exact_snippets": "have exhausted systemic therapies with regular approval for their disease",
                    "criterion": "systemic therapies with regular approval for their disease",
                    "requirements": [
                        {
                            "requirement_type": "exhaustion",
                            "expected_value": true
                        }
                    ]
                }
            ]
        }
    ],
    "exclusion_lines": [
        {
            "line": "* Prior treatment with AFM13",
            "criterions": [
                {
                    "exact_snippets": "Prior treatment with AFM13",
                    "criterion": "prior treatment with AFM13",
                    "requirements": [
                        {
                            "requirement_type": "history",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Requirement for systemic immunosuppressive therapy, e.g. GvHD therapy, <12 weeks prior to the first dose of study drug.",
            "criterions": [
                {
                    "exact_snippets": "Requirement for systemic immunosuppressive therapy ... <12 weeks prior to the first dose of study drug.",
                    "criterion": "systemic immunosuppressive therapy",
                    "requirements": [
                        {
                            "requirement_type": "requirement for therapy",
                            "expected_value": true
                        },
                        {
                            "requirement_type": "timing before first dose",
                            "expected_value": {
                                "operator": "<",
                                "value": 12,
                                "unit": "weeks"
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Has had an allogenic tissue hematopoietic cell/solid organ transplant within the last 3 years. Note: Patients who have had a transplant >3 years ago are eligible as long as there are no signs/symptoms of graft versus host disease (GvHD).",
            "criterions": [
                {
                    "exact_snippets": "Has had an allogenic tissue hematopoietic cell/solid organ transplant within the last 3 years",
                    "criterion": "allogenic tissue hematopoietic cell/solid organ transplant",
                    "requirements": [
                        {
                            "requirement_type": "history",
                            "expected_value": true
                        },
                        {
                            "requirement_type": "time since transplant",
                            "expected_value": {
                                "operator": "<=",
                                "value": 3,
                                "unit": "years"
                            }
                        }
                    ]
                },
                {
                    "exact_snippets": "Patients who have had a transplant >3 years ago are eligible as long as there are no signs/symptoms of graft versus host disease (GvHD)",
                    "criterion": "graft versus host disease (GvHD)",
                    "requirements": [
                        {
                            "requirement_type": "signs/symptoms",
                            "expected_value": false
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Patients with the following subtypes of lymphoma: T-cell prolymphocytic leukemia; T-cell large granular lymphocytic leukemia; Chronic lymphoproliferative disorder of NK cells; Aggressive NK-cell leukemia; Extranodal NK-/T-cell lymphoma; Indolent T-cell lymphoproliferative disorder of the GI tract:",
            "criterions": [
                {
                    "exact_snippets": "T-cell prolymphocytic leukemia",
                    "criterion": "T-cell prolymphocytic leukemia",
                    "requirements": [
                        {
                            "requirement_type": "diagnosis",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "T-cell large granular lymphocytic leukemia",
                    "criterion": "T-cell large granular lymphocytic leukemia",
                    "requirements": [
                        {
                            "requirement_type": "diagnosis",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "Chronic lymphoproliferative disorder of NK cells",
                    "criterion": "Chronic lymphoproliferative disorder of NK cells",
                    "requirements": [
                        {
                            "requirement_type": "diagnosis",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "Aggressive NK-cell leukemia",
                    "criterion": "Aggressive NK-cell leukemia",
                    "requirements": [
                        {
                            "requirement_type": "diagnosis",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "Extranodal NK-/T-cell lymphoma",
                    "criterion": "Extranodal NK-/T-cell lymphoma",
                    "requirements": [
                        {
                            "requirement_type": "diagnosis",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "Indolent T-cell lymphoproliferative disorder of the GI tract",
                    "criterion": "Indolent T-cell lymphoproliferative disorder of the GI tract",
                    "requirements": [
                        {
                            "requirement_type": "diagnosis",
                            "expected_value": true
                        }
                    ]
                }
            ]
        }
    ],
    "miscellaneous_lines": [
        {
            "line": "Main",
            "criterions": [
                {
                    "exact_snippets": "Main",
                    "criterion": "main criterion",
                    "requirements": [
                        {
                            "requirement_type": "N/A",
                            "expected_value": "Main"
                        }
                    ]
                }
            ]
        }
    ],
    "failed_inclusion": [],
    "failed_exclusion": [],
    "failed_miscellaneous": []
}